Avior Wealth Management LLC Raises Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Avior Wealth Management LLC lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 22.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,123 shares of the biotechnology company’s stock after purchasing an additional 384 shares during the quarter. Avior Wealth Management LLC’s holdings in Repligen were worth $382,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of RGEN. Fortis Capital Advisors LLC purchased a new position in shares of Repligen during the fourth quarter worth about $35,000. Park Place Capital Corp grew its holdings in shares of Repligen by 90.2% during the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 120 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 86 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Repligen during the third quarter worth about $51,000. Finally, UniSuper Management Pty Ltd bought a new stake in Repligen in the 2nd quarter worth approximately $57,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on RGEN. Stifel Nicolaus boosted their target price on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. KeyCorp boosted their target price on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $196.70.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the transaction, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock worth $5,039,532 over the last quarter. 1.20% of the stock is owned by corporate insiders.

Repligen Price Performance

Shares of Repligen stock opened at $157.06 on Friday. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.77 billion, a PE ratio of 218.14, a P/E/G ratio of 5.27 and a beta of 1.02. The business has a 50 day moving average of $190.02 and a 200 day moving average of $173.20. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million during the quarter, compared to the consensus estimate of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm’s revenue for the quarter was down 16.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 earnings per share. As a group, equities research analysts forecast that Repligen Co. will post 1.46 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.